Clinuvel Pharmaceuticals Ltd. Company Profile | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd.
Stock Exchange	Other OTC
EPS	$0.24
Market Cap	$1.16 B
Shares Outstanding	47.82 M
Public Float	-

Clinuvel Pharmaceuticals Ltd. ADR
Stock Exchange	Other OTC
EPS	$0.24
Market Cap	$1.14 B
Shares Outstanding	48.96 M
Public Float	-

Clinuvel Pharmaceuticals Ltd.
Stock Exchange	Australian Stock Exchange
EPS	AUD0.32
Market Cap	AUD1.63 B
Shares Outstanding	48.96 M
Public Float	36.67 M

Clinuvel Pharmaceuticals Ltd.
Stock Exchange	Frankfurt Stock Exchange
EPS	-
Market Cap	-
Shares Outstanding	47.86 M
Public Float	-

Profile

Address	15 Queen Street Melbourne Victoria (VIC) 3000 Australia
Employees	-
Website	http://www.clinuvel.com
Updated	07/08/2019
Clinuvel Pharmaceuticals Ltd. is a global biopharmaceutical company. It engages in the the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders.

Financials

Philippe J. Wolgen

Chief Executive Officer, MD & Director

Stanley R. McLiesh

Non-Executive Chairman